Deep Dive #15: Adeno-Associated Virus (AAV) Delivery

BIOS: Nucleus of Life Science Innovation 🚀

JOBS

• BIOS Talent: Find Jobs @ Breakout TechBio Startups  —  Search Jobs 🚀

• Post Jobs: Add Your Startup to BIOS Talent  —  Post Now 🎉

• Students: Join Alix Ventures Fellowship  —  Join Now 🧬

• BIOS Contributor: Share Your Thought Leadership  —  Join Now🔬

CONTENT & COMMUNITY

• BIOS Daily: Join 25K+ Subscribers Following TechBio  —  Sign Up 🔥

• BIOS Insider: Premium TechBio Thought Leadership  —  Sign Up ✨

• BIOS Commons: World’s Largest #TechBio Community  —  Join Now 🎉

INVEST

• BIOS Angels: 1st TechBio Angel Investing Syndicate  —  Join Now 🌟

• Alix Limited: Invest in Breakout TechBio Startups  —  Learn More 🧠

By:

Alix Ventures: Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human Health

---

Overview

25 years ago, Adeno Associated Virus (AAV) had almost no industry specific interest - labeled as purely “academic” research. Fast forward to present day & the landscape is busier than ever. Emerging AAV based companies are prevalent all throughout the world from emerging startups all the way to large scale pharmaceutical companies - with 2021 serving as a breakout year where we saw VC investment rocket up 39% in the category.

The AAV Vector-Based Gene Therapy market size is anticipated to grow exponentially over the coming years with the increase in the approval of a growing number of gene therapies, ability to treat a broad array of conditions, the promise of convenient one-time dosing, & the potential for curative treatment options.